The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...
The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...
U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
The blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more ...
The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
It is a major victory for market-driven medication development. Chris Boerner, board chair and chief executive officer at ...